Renhaim Therapeutics, a leading innovator in the biotechnology sector, marked a significant milestone on June 7, 2023 by establishing a strategic partnership with PeproMene Bio, a cutting-edge cell biotech based in the United States. The primary objective of this collaboration is to expedite the progress of gene and cell therapy initiatives.
In a strategic move to amplify our expertise in this realm, Renhaim has enlisted the distinguished Dr. Larry Kwak to join our Scientific Advisory Board (SAB). Dr. Kwak, renowned for his pivotal role in developing the core technology at PeproMene Bio, brings a wealth of experience and insight to our collaborative efforts.
Dr. Larry W. Kwak currently serves as the Vice President of City of Hope, one of the largest cancer centers in the United States. His remarkable contributions to the field of medicine have earned him esteemed accolades, including being named one of TIME100’s the most influential people globally in 2010. Notably, Dr. Kwak has been honored with the Ho-Am Award in Medicine in 2016, recognizing his groundbreaking contributions that have opened new horizons in medical research.
As global interest in the cancer vaccine sector continues to rise, the addition of Dr. Larry W. Kwak to our Scientific Advisory Board is poised to catapult our endeavors in the cancer vaccine field. His role as a pioneer in the cancer vaccine field and as the developer of core technology (BAFFR-CAR T) aligns seamlessly with our commitment to advancing breakthroughs in medical innovation.
The collaboration with PeproMene Bio coupled with the expertise of Dr. Kwak, underscores our dedication to accelerating progress in therapy, ultimately contributing to the advancements in the cancer vaccine field on a global scale.
For more details, please refer to the link below.
